Table 3. Multivariate analysis of a Cox’s hazard model in relation to progression-free survival and overall survival (weighted cohort).
| Variables | Progression-free survival | Overall survival | |||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age (yr) | |||||
| ≤55 | Reference | 0.513 | Reference | 0.591 | |
| >55 | 1.044 (0.860–1.266) | 0.937 (0.741–1.187) | |||
| FIGO stage | |||||
| II | Reference | <0.001 | Reference | <0.001 | |
| III–IV | 2.672 (1.977–3.611) | 2.444 (1.716–3.480) | |||
| Residual tumor | |||||
| None | Reference | <0.001 | Reference | <0.001 | |
| <1 cm | 1.567 (1.234–1.990) | 1.562 (1.158–2.107) | |||
| Surgery | |||||
| Non-RLNA | Reference | 0.002 | Reference | <0.001 | |
| RLNA | 0.742 (0.613–0.899) | 0.620 (0.488–0.787) | |||
| Chemotherapy | |||||
| Non-TP | Reference | 0.762 | Reference | 0.021 | |
| TP | 0.961 (0.743–1.243) | 0.709 (0.530–0.949) | |||
| Treatment era | |||||
| <2010 | Reference | 0.034 | Reference | 0.832 | |
| ≥2010 | 1.252 (1.017–1.540) | 0.970 (0.734–1.283) | |||
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; RLNA, retroperitoneal lymphadenectomy; TP, taxane plus platinum.